Projecting future drug expenditures - 2012

James M. Hoffman, Edward Li, Fred Doloresco, Linda Matusiak, Robert J. Hunkler, Nilay D Shah, Lee C. Vermeulen, Glen T. Schumock

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Purpose. Factors likely to influence drug expenditures, drug expenditure trends in 2010 and 2011, and projected drug expenditures for 2012 are discussed. Summary. Data were analyzed to provide drug expenditure trends for total drug expenditures and the hospital and clinic sectors. Data were obtained from the IMS Health National Sales Perspectives database. From 2009 to 2010, total U.S. drug expenditures increased by 2.7%, with total spending rising from $299.2 billion to $307.5 billion. Drug expenditures in clinics grew by 6.0% from 2009 to 2010. Hospital drug expenditures increased at the moderate rate of 1.5% from 2009 to 2010; through the first nine months of 2011, hospital drug expenditures increased by only 0.3% compared with the same period in 2010. The dominant trend over the past several years is substantial moderation in expenditure growth for widely used drugs, primarily due to the ongoing introduction and wide use of generic versions of high-cost, frequentlyused medications. At the end of 2010, generic drugs accounted for 78% of all retail prescriptions dispensed. Another pattern is substantial increases in expenditures for specialized medications, particularly in the outpatient setting as growth in prescription drug expenditures for clinic-administered drugs consistently outpaces growth in total expenditures. Various factors are likely to influence drug expenditures in 2012, including drugs in development, the diffusion of new drugs, generic drugs, drug shortages, and biosimilars. Conclusion. For 2012, we project a 3-5% increase in total drug expenditures across all settings, a 5-7% increase in expenditures for clinic-administered drugs, and a 0-2% increase in hospital drug expenditures.

Original languageEnglish (US)
Pages (from-to)405-421
Number of pages17
JournalAmerican Journal of Health-System Pharmacy
Volume69
Issue number5
DOIs
StatePublished - Mar 1 2012

Fingerprint

Health Expenditures
Pharmaceutical Preparations
Generic Drugs
Biosimilar Pharmaceuticals
Growth
Prescription Drugs
Population Growth

Keywords

  • Ambulatory care
  • Costs
  • Drug distribution
  • Drugs
  • Economics
  • Hospitals
  • Prescriptions
  • Product development

ASJC Scopus subject areas

  • Pharmacology
  • Health Policy

Cite this

Hoffman, J. M., Li, E., Doloresco, F., Matusiak, L., Hunkler, R. J., Shah, N. D., ... Schumock, G. T. (2012). Projecting future drug expenditures - 2012. American Journal of Health-System Pharmacy, 69(5), 405-421. https://doi.org/10.2146/ajhp110697

Projecting future drug expenditures - 2012. / Hoffman, James M.; Li, Edward; Doloresco, Fred; Matusiak, Linda; Hunkler, Robert J.; Shah, Nilay D; Vermeulen, Lee C.; Schumock, Glen T.

In: American Journal of Health-System Pharmacy, Vol. 69, No. 5, 01.03.2012, p. 405-421.

Research output: Contribution to journalArticle

Hoffman, JM, Li, E, Doloresco, F, Matusiak, L, Hunkler, RJ, Shah, ND, Vermeulen, LC & Schumock, GT 2012, 'Projecting future drug expenditures - 2012', American Journal of Health-System Pharmacy, vol. 69, no. 5, pp. 405-421. https://doi.org/10.2146/ajhp110697
Hoffman JM, Li E, Doloresco F, Matusiak L, Hunkler RJ, Shah ND et al. Projecting future drug expenditures - 2012. American Journal of Health-System Pharmacy. 2012 Mar 1;69(5):405-421. https://doi.org/10.2146/ajhp110697
Hoffman, James M. ; Li, Edward ; Doloresco, Fred ; Matusiak, Linda ; Hunkler, Robert J. ; Shah, Nilay D ; Vermeulen, Lee C. ; Schumock, Glen T. / Projecting future drug expenditures - 2012. In: American Journal of Health-System Pharmacy. 2012 ; Vol. 69, No. 5. pp. 405-421.
@article{b52bcc4788754cff9c2915659f28747a,
title = "Projecting future drug expenditures - 2012",
abstract = "Purpose. Factors likely to influence drug expenditures, drug expenditure trends in 2010 and 2011, and projected drug expenditures for 2012 are discussed. Summary. Data were analyzed to provide drug expenditure trends for total drug expenditures and the hospital and clinic sectors. Data were obtained from the IMS Health National Sales Perspectives database. From 2009 to 2010, total U.S. drug expenditures increased by 2.7{\%}, with total spending rising from $299.2 billion to $307.5 billion. Drug expenditures in clinics grew by 6.0{\%} from 2009 to 2010. Hospital drug expenditures increased at the moderate rate of 1.5{\%} from 2009 to 2010; through the first nine months of 2011, hospital drug expenditures increased by only 0.3{\%} compared with the same period in 2010. The dominant trend over the past several years is substantial moderation in expenditure growth for widely used drugs, primarily due to the ongoing introduction and wide use of generic versions of high-cost, frequentlyused medications. At the end of 2010, generic drugs accounted for 78{\%} of all retail prescriptions dispensed. Another pattern is substantial increases in expenditures for specialized medications, particularly in the outpatient setting as growth in prescription drug expenditures for clinic-administered drugs consistently outpaces growth in total expenditures. Various factors are likely to influence drug expenditures in 2012, including drugs in development, the diffusion of new drugs, generic drugs, drug shortages, and biosimilars. Conclusion. For 2012, we project a 3-5{\%} increase in total drug expenditures across all settings, a 5-7{\%} increase in expenditures for clinic-administered drugs, and a 0-2{\%} increase in hospital drug expenditures.",
keywords = "Ambulatory care, Costs, Drug distribution, Drugs, Economics, Hospitals, Prescriptions, Product development",
author = "Hoffman, {James M.} and Edward Li and Fred Doloresco and Linda Matusiak and Hunkler, {Robert J.} and Shah, {Nilay D} and Vermeulen, {Lee C.} and Schumock, {Glen T.}",
year = "2012",
month = "3",
day = "1",
doi = "10.2146/ajhp110697",
language = "English (US)",
volume = "69",
pages = "405--421",
journal = "American Journal of Health-System Pharmacy",
issn = "1079-2082",
publisher = "American Society of Health-Systems Pharmacy",
number = "5",

}

TY - JOUR

T1 - Projecting future drug expenditures - 2012

AU - Hoffman, James M.

AU - Li, Edward

AU - Doloresco, Fred

AU - Matusiak, Linda

AU - Hunkler, Robert J.

AU - Shah, Nilay D

AU - Vermeulen, Lee C.

AU - Schumock, Glen T.

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Purpose. Factors likely to influence drug expenditures, drug expenditure trends in 2010 and 2011, and projected drug expenditures for 2012 are discussed. Summary. Data were analyzed to provide drug expenditure trends for total drug expenditures and the hospital and clinic sectors. Data were obtained from the IMS Health National Sales Perspectives database. From 2009 to 2010, total U.S. drug expenditures increased by 2.7%, with total spending rising from $299.2 billion to $307.5 billion. Drug expenditures in clinics grew by 6.0% from 2009 to 2010. Hospital drug expenditures increased at the moderate rate of 1.5% from 2009 to 2010; through the first nine months of 2011, hospital drug expenditures increased by only 0.3% compared with the same period in 2010. The dominant trend over the past several years is substantial moderation in expenditure growth for widely used drugs, primarily due to the ongoing introduction and wide use of generic versions of high-cost, frequentlyused medications. At the end of 2010, generic drugs accounted for 78% of all retail prescriptions dispensed. Another pattern is substantial increases in expenditures for specialized medications, particularly in the outpatient setting as growth in prescription drug expenditures for clinic-administered drugs consistently outpaces growth in total expenditures. Various factors are likely to influence drug expenditures in 2012, including drugs in development, the diffusion of new drugs, generic drugs, drug shortages, and biosimilars. Conclusion. For 2012, we project a 3-5% increase in total drug expenditures across all settings, a 5-7% increase in expenditures for clinic-administered drugs, and a 0-2% increase in hospital drug expenditures.

AB - Purpose. Factors likely to influence drug expenditures, drug expenditure trends in 2010 and 2011, and projected drug expenditures for 2012 are discussed. Summary. Data were analyzed to provide drug expenditure trends for total drug expenditures and the hospital and clinic sectors. Data were obtained from the IMS Health National Sales Perspectives database. From 2009 to 2010, total U.S. drug expenditures increased by 2.7%, with total spending rising from $299.2 billion to $307.5 billion. Drug expenditures in clinics grew by 6.0% from 2009 to 2010. Hospital drug expenditures increased at the moderate rate of 1.5% from 2009 to 2010; through the first nine months of 2011, hospital drug expenditures increased by only 0.3% compared with the same period in 2010. The dominant trend over the past several years is substantial moderation in expenditure growth for widely used drugs, primarily due to the ongoing introduction and wide use of generic versions of high-cost, frequentlyused medications. At the end of 2010, generic drugs accounted for 78% of all retail prescriptions dispensed. Another pattern is substantial increases in expenditures for specialized medications, particularly in the outpatient setting as growth in prescription drug expenditures for clinic-administered drugs consistently outpaces growth in total expenditures. Various factors are likely to influence drug expenditures in 2012, including drugs in development, the diffusion of new drugs, generic drugs, drug shortages, and biosimilars. Conclusion. For 2012, we project a 3-5% increase in total drug expenditures across all settings, a 5-7% increase in expenditures for clinic-administered drugs, and a 0-2% increase in hospital drug expenditures.

KW - Ambulatory care

KW - Costs

KW - Drug distribution

KW - Drugs

KW - Economics

KW - Hospitals

KW - Prescriptions

KW - Product development

UR - http://www.scopus.com/inward/record.url?scp=84857591730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857591730&partnerID=8YFLogxK

U2 - 10.2146/ajhp110697

DO - 10.2146/ajhp110697

M3 - Article

C2 - 22345420

AN - SCOPUS:84857591730

VL - 69

SP - 405

EP - 421

JO - American Journal of Health-System Pharmacy

JF - American Journal of Health-System Pharmacy

SN - 1079-2082

IS - 5

ER -